D-Glucose
|
Basic information |
| Metabolite name | D-Glucose |
 | HMDB0000122 |
 |
C00221 |
 |
5793 |
| Synonyms | glucose |
| No. of studies | 55 |
|
Basic information |
| Metabolite name | D-Glucose |
| HMDB0000122 |
|
C00221 |
|
5793 |
| Synonyms | glucose |
| No. of studies | 55 |
|
Relationship between D-Glucose and depression (count: 55) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M005 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M009 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + middle dose of Xiaoyaosan group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M009 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M013 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Up |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M035 | Type1 | depressed suicide attempters group vs. control group | Plasma | Human | Up |
| Study M041 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M059 | Type2 | Xiaoyaosan-treated depressed group 10-week vs. baseline | Plasma | Human | Up |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M078 | Type1 | CORT model group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M078 | Type2 | CORT model + icariin group vs. CORT model group | Serum | Sprague-Dawley rat | Up |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Up |
| Study M093 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M093 | Type2 | paroxetine group vs. baseline | Serum | Human | Up |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Down |
| Study M103 | Type1 | stress group vs. control group | Plasma | C57BL/6 mouse | Unknown |
| Study M1044 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Liver | CD-1 mouse | Up |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type1 | adult high-fat diet group vs. adult control group | Liver | CD-1 mouse | Down |
| Study M1048 | Type1 | juvenile high-fat diet group vs. juvenile control group | Faece | CD-1 mouse | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type2 | adult high-fat diet + probiotic group vs. adult high-fat diet group | Liver | CD-1 mouse | Up |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Plasma | CD-1 mouse | Down |
| Study M1048 | Type3 | adult probiotic group vs. adult control group | Liver | CD-1 mouse | Up |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1066 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Amygdala | Cynomolgus monkey | Down |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type1 | CMS group vs. control group | Ventral hippocampus | Wistar rat | Down |
| Study M1092 | Type2 | CMS + venlafaxine group vs. CMS group | Ventral hippocampus | Wistar rat | Up |
| Study M113 | Type1 | CUMS group vs. control group | Serum | Wistar rat | Down |
| Study M113 | Type2 | CUMS + exercise group vs. CUMS group | Serum | Wistar rat | Up |
| Study M116 | Type3 | LY group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Down |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M292 | Type1 | cLH group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M292 | Type3 | ECS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M339 | Type1 | depression group vs. control group | Pregenual anterior cingulate cortex | Human | Up |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M543 | Type1 | summer depression group vs. summer control group | Plasma | Human | Down |
| Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Plasma | Human | Unknown |
| Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
| Study M610 | Type1 | CUMS group vs. control group | Kidney | Sprague-Dawley rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Liver | Sprague-Dawley rat | Unknown |
| Study M611 | Type1 | LPS group vs. control group | Kidney | Sprague-Dawley rat | Unknown |
| Study M613 | Type2 | CSDS susceptible + imipramine group vs. CSDS + vehicle group | Serum | C57BL/6 J mouse | Up |
| Study M615 | Type1 | high-fat diet group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M619 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M619 | Type2 | CUMS + middle dose of Jiaotaiwan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M642 | Type1 | SDS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M668 | Type1 | PSD group vs. stroke group | Urine | Human | Down |
| Study M683 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M712 | Type1 | depression group vs. control group | Prefrontal cortex | Cynomolgus monkey | Down |
| Study M768 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M768 | Type2 | depression group, after vs. before fluoxetine treatment | Serum | Human | Down |
| Study M790 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M790 | Type2 | CUMS + venlafaxine group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M790 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Liver | Sprague-Dawley rat | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M843 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M873 | Type1 | ovariectomy + CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M873 | Type2 | ovariectomy + CUMS + Xiang-Su volatile oil group vs. ovariectomy + CUMS group | Plasma | Sprague-Dawley rat | Up |
| Study M921 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M924 | Type2 | CUMS + aerobic exercise group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M943 | Type1 | CUMS group vs. control group | Liver | ICR mouse | Down |
| Study M943 | Type2 | CUMS + low dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + fluoxetine group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + middle dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M943 | Type2 | CUMS + high dose of Acanthopanax senticosus Harms group vs. CUMS group | Liver | ICR mouse | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M971 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M980 | Type1 | CMS group vs. control group | Olfactory bulb | C57BL/6J mouse | Down |